Who will take the sell side of a blobspace derivatives market, and how can we limit their risk?

In this post, I solve for payoff bounds and demonstrate how we can make conditions more favorable for sellers:

mirror.xyz/tamaratran.eth…

Bladder cancer TME-specific TGF-β & hypoxia directly suppress NK cell function via O2-dependent reduction in SLAMF6 signaling Adam Farkas Bhardwaj Lab Michelle Alyssa Tran, PhD Michelle Alyssa Tran, PhD Dr. John Sfakianos Horowitz Lab @Icahn School of Medicine Mount Sinai
biorxiv.org/content/10.110…

Congrats to Adam Farkas for leading this study and elegantly unraveling the role of tissue-specific factors such as hypoxia in suppression of NK cell function in cancer!

biorxiv.org/content/10.110…

Happy International Day of Immunology!

Today we celebrate the incredible advancements in immunology that help protect us from disease and pave the way for healthier futures.

What are you doing to celebrate? Post and tag us for a chance to be featured!

My sister is building a fintech company! Learn more ⬇️!

6/ Thanks to barnabe.eth, Lane 'one meme behind' Rettig, James Prestwich, Life is short, so am I, sydney and neelsalami.eth 🌑 for the collaboration & edits.

If you're interested in working on these problems, please reach out. I would love to collaborate and connect with other engineers working in the space.

5/ So far, the biggest challenges to me are: (1) the burned base fee making the derivative unsuitable for the natural seller (validators), (2) enabling physical delivery, and (3) protecting against manipulation.

Some more reading on this here: mirror.xyz/0x03c29504CEcC…

4/ Typically, gas markets suffer from lack of a natural seller. In this case, speculators in the community have long argued that the price for blobs should go down over time as bandwidth scales.

I expect that the market will be primarily speculators collecting premiums to start

3/ Blobspace derivatives aim to hedge against these volatility challenges.

Similarly to trading of commodities futures, establishing derivatives markets for blob gas fees creates strategic trading opportunities for rollups (who pay premiums to de-risk their operational costs)

2/ The Dencun upgrade enabled record-high usage and 10x lower fees for L2s with blobs.

However, 10,000%+ gas spikes via Inscriptions soon highlighted their price volatility during high network demand. Future congestion events threaten more unpredictable costs for rollups.

1/ Blobs unlock unprecedented scaling for L2s, but have huge gas spikes and price volatility. They lack financialization like hedging and fractionalization.

I've just quit my job at Apple to build blobspace derivatives & contribute to the ETH ecosystem:

mirror.xyz/0x1Ca8D5E43A19…

Med by Cell Press Judy Cho @MSHS_IBDCenter MountSinai Pathology SinaiMSTP With directly sampled fistulous tracts ( MountSinai Pathology ), a diverse patient cohort (@MSHS_IBDCenter , Colleen Chasteau, Ujunwa Korie, Diana Paguay), & layered multi-omic approaches we identified key contributors to fistula pathogenesis with therapeutic potential

I am so thrilled that our study defining mechanisms of #PerianalFistula in #Crohns disease is now out in Med by Cell Press . Thank you to Judy Cho + team, Mount Sinai IBD Center MountSinai Pathology SinaiMSTP , and the patients who made this possible
doi.org/10.1016/j.medj…

Beautiful spring afternoon in Central Park spent making bouquets and celebrating our newly matched students as well as those going through other program/ life milestones! 💐

It’s always a lovely time celebrating everyone’s successes & hard work!

Beyond excited to share that my project from Mackall Lab and Stanford Medicine, led by my incredible postdoc-turned-PI Evan Weber, in collaboration with his new(ish) lab at Children's Hospital, is now published in Nature! Check it out here:

nature.com/articles/s4158…

What a group! Congrats Miriam Merad, MD, PhD Bhardwaj Lab !

MODERN is open! Available at your site through the CRSU. Please help advance MRD-based adjuvant decision making in bladder cancer. Alliance for Clinical Trials in Oncology Alan Tan Ashish M. Kamat, MD, MBBS ECOG-ACRIN Cancer Research Group SWOG Cancer Research Network Guru P. Sonpavde, MD PaulCrispenMD Stephanie Berg Suzanne Cole, MD Nitin Yerram M.D. DrTylerStewart Jonathan Rosenberg MD

Thank you Cancer Research Institute for featuring me amongst many fantastic women for Women’s Month! I am very grateful to be one of your postdoctoral fellows!

Researchers at Bhardwaj Lab and Dr. Michelle Krogsgaard lab describe a molecular mechanism by which the neoantigen Hsf2 p.K72N is recognized by a corresponding high affinity Hsf2 p.K72N-reactive T cell receptor, 47BE7, from the mouse melanoma line B16F10.

nature.com/articles/s4146…